Covid-19 in patients with inflammatory bowel diseases: rates and courses of infection, rates of vaccination, potential side effects and antibody titers - An evaluation at the outpatient clinic for IBD of the University Hospital Heidelberg

Covid-19 in patients with inflammatory bowel diseases: rates and courses of infection, rates of vaccination, potential side effects and antibody titers - An evaluation at the outpatient clinic for IBD of the University Hospital Heidelberg - Covid19CED

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00027218

Enrollment

400

Registered

2021-11-15

Start date

2021-11-16

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19 Inflammatory Bowel Diseases

Interventions

Group 1: The study is an observational cohort study with only one group. All patients are asked to fill in a questionnaire on potential Covid-19 infections, theit courses and vaccinations against Covi

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: a) Patient with ulcerative colitis or Crohn's disease reliably diagnosed according to the criteria of the DGVS (German Society for Digestive and Metabolic Diseases) b) Age from 18 years d) Treatment in the Department of Internal Medicine IV of the Heidelberg University Hospital at the time of sample collection e) The patient is able to give consent. f) Signed declaration of consent

Exclusion criteria

Exclusion criteria: Failure to meet the inclusion criteria

Design outcomes

Primary

Measure	Time frame
The main objectives of the project are: 1. to record the prevalence of SARS-CoV2 infection in our IBD cohort, 2. Describe the severity of any SARS-CoV2 infections you may have had (hospitalization, intensive care treatment), 3. to record the vaccination rates against SARS-CoV2 in our cohort, 4. Describe the serological response (S and N antibodies) to SARS-CoV2 infection and vaccinations at different times, and 5. To record possible side effects of the vaccinations, especially with regard to the course of IBD.	—

Measure

Time frame

The main objectives of the project are: 1. to record the prevalence of SARS-CoV2 infection in our IBD cohort, 2. Describe the severity of any SARS-CoV2 infections you may have had (hospitalization, intensive care treatment), 3. to record the vaccination rates against SARS-CoV2 in our cohort, 4. Describe the serological response (S and N antibodies) to SARS-CoV2 infection and vaccinations at different times, and 5. To record possible side effects of the vaccinations, especially with regard to the course of IBD.

—

Secondary

Measure	Time frame
In a further step, possible connections between disease activity of IBD, immunosuppressive therapy and both the severity of a possible SARS-CoV2 infection and the serological vaccination response are to be established. (knowing that the informative value of a serological evaluation alone is limited).	—

Countries

Germany

Contacts

Public ContactAnnika Gauss

Universitätsklinikum Heidelberg

annika.gauss@med.uni-heidelberg.de062215638865

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026